TT Xenograft Model Overview
The TT xenograft model is derived from a human thyroid cancer cell line, TT, which was established from a primary tumor in a patient with differentiated thyroid carcinoma (DTC). Thyroid cancer is the most common endocrine malignancy, and DTC, including papillary and follicular thyroid cancers, represents the majority of thyroid cancer cases. Despite being less aggressive than anaplastic thyroid cancer, DTC can still lead to metastasis, particularly to the lungs and lymph nodes. The TT xenograft model is valuable for preclinical research, providing a platform to study thyroid cancer biology, tumor progression, metastasis, and resistance to standard therapies, such as radioactive iodine (RAI) therapy. Given its ability to replicate key features of thyroid cancer, including its genetic mutations and receptor expression profiles, the TT xenograft model is ideal for evaluating new therapeutic strategies, including targeted therapies, immune therapies, and combination regimens.
Request a Custom Quote for TT Xenograft ModelBiological and Molecular Characteristics
TT cells are characterized by their differentiated thyroid cancer origin and express thyroid-specific markers, including thyroglobulin (TG) and sodium-iodide symporter (NIS), which are involved in iodine uptake. These cells also harbor mutations in the RET proto-oncogene, which plays a critical role in thyroid cancer pathogenesis and metastasis. RET mutations are particularly common in medullary thyroid cancer (MTC), but they are also implicated in a subset of differentiated thyroid cancers. In addition to RET mutations, TT cells exhibit dysregulated signaling in the MAPK/ERK pathway, which promotes cell proliferation, survival, and invasion. The model also demonstrates overexpression of vascular endothelial growth factor (VEGF), contributing to angiogenesis and tumor growth. These molecular features make the TT xenograft model particularly useful for studying therapies aimed at inhibiting these key pathways, including kinase inhibitors and anti-angiogenic agents.
| Marker | Expression Level | Function |
|---|---|---|
| Thyroglobulin (TG) | High | Thyroid-specific marker |
| Sodium-Iodide Symporter (NIS) | High | Essential for iodine uptake in thyroid cells |
| RET | Mutated | Oncogene involved in tumor progression and metastasis |
| VEGF | Elevated | Angiogenesis factor promoting tumor growth |
In Vivo Model Development and Tumorigenicity
The TT xenograft model is typically established by implanting TT cells into immunocompromised mice, such as NOD/SCID or NSG mice, which lack functional T and B cells. Upon implantation, the cells form tumors that closely resemble human differentiated thyroid carcinoma, including the presence of thyroid-specific markers like thyroglobulin and NIS. These tumors exhibit high cellularity, significant vascularization, and areas of necrosis, reflecting the rapid growth of the tumor. The TT xenograft model is particularly valuable for evaluating the effects of chemotherapy agents, radioactive iodine (RAI) therapy, and targeted therapies such as tyrosine kinase inhibitors (TKIs), which target the RET mutation and the MAPK/ERK signaling pathway.
In addition to subcutaneous implantation, orthotopic models of TT can be established by implanting the cells directly into the thyroid gland of immunocompromised mice. This orthotopic model more accurately mimics the natural site of tumor growth, allowing for the study of local invasion, metastasis, and the effects of treatment on the tumor microenvironment. The ability of TT tumors to metastasize to distant organs, such as the lungs and lymph nodes, makes this model ideal for studying metastatic disease and evaluating therapies aimed at preventing or treating metastasis in thyroid cancer.
Request a Custom Quote for TT Xenograft ModelHistopathology and Immunohistochemical Profile
Histopathological examination of TT xenografts reveals the characteristic features of differentiated thyroid carcinoma, including follicular or papillary structures and areas of necrosis due to rapid tumor growth. Immunohistochemical staining of TT xenografts shows strong expression of thyroglobulin (TG) and sodium-iodide symporter (NIS), confirming the thyroid origin of the tumor. RET mutations can be detected using specific probes, reflecting the role of the RET oncogene in tumorigenesis. Additionally, elevated levels of VEGF are observed in TT xenografts, highlighting the role of angiogenesis in sustaining tumor growth. The tumors also show high levels of phosphorylated AKT and ERK, indicating the activation of the PI3K/AKT and MAPK/ERK signaling pathways, which contribute to tumor survival, proliferation, and resistance to therapy. CD31 staining reveals significant vascularization, reflecting the importance of blood vessel formation in supporting tumor growth.
Preclinical Applications and Drug Response
The TT xenograft model is widely used to evaluate the efficacy of various therapeutic agents for thyroid cancer. The model is particularly useful for testing chemotherapy agents, radioactive iodine (RAI) therapy, and targeted therapies such as tyrosine kinase inhibitors (TKIs), which target the RET mutation and associated signaling pathways like MAPK/ERK and PI3K/AKT. Given the model’s ability to develop resistance to RAI therapy and chemotherapy over time, it is highly valuable for studying the mechanisms of therapy resistance and testing new agents aimed at overcoming these challenges.
In addition to chemotherapy and targeted therapies, the TT xenograft model is increasingly used to evaluate the potential of immunotherapies, including immune checkpoint inhibitors and monoclonal antibodies targeting cancer-specific antigens. The model’s ability to replicate key features of differentiated thyroid cancer, including its aggressive growth, metastasis, and resistance to therapy, makes it an ideal system for studying new treatment strategies. Furthermore, the ability of TT xenografts to metastasize to distant organs provides an excellent opportunity to evaluate therapies aimed at preventing or treating metastatic disease in thyroid cancer.
Request This Model
To request the TT xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for TT Xenograft Model